Stopping MS medication in older adults with stable multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at whether it is safe for people aged 55 and older with stable multiple sclerosis to stop taking their MS medication. It compares stopping the medication versus continuing it, to see if stopping is safe and does not lead to new disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years old or older.
- You have had multiple sclerosis (relapsing-remitting) for more than 5 years.
- Your MS has been stable for the last 5 years: no relapses, no new brain changes on MRI, and no worsening of disability.
- You have been on a standard (first-line) MS medication, such as interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide, for at least the last 5 years.
- You are open to possibly stopping your MS medication as part of this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
This trial looks at two ways to treat multiple sclerosis (MS) that begins after age 50. It compares starting with a stronger medication right away versus starting with a milder one and then switching if needed.
This study looks at how a failed treatment affects the emotional and social experiences of people with relapsing-remitting MS. If you qualify, you'll be asked to complete questionnaires about your feelings and daily life.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Hear when a new Relapsing-remitting Multiple Sclerosis (RRMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.